S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
The World's First "$20 Trillion Drug (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Something is Coming for America's Top Stock (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
Biden's campaign joins TikTok, even as administration warns of national security concerns with app
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
The World's First "$20 Trillion Drug (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Something is Coming for America's Top Stock (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
Biden's campaign joins TikTok, even as administration warns of national security concerns with app
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
The World's First "$20 Trillion Drug (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Something is Coming for America's Top Stock (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
Biden's campaign joins TikTok, even as administration warns of national security concerns with app
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
The World's First "$20 Trillion Drug (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Something is Coming for America's Top Stock (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
Biden's campaign joins TikTok, even as administration warns of national security concerns with app

Vaccine Stocks List

Compare vaccine stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Learn more about trading vaccine stocks.

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$73.67
-0.2%
$80.74
$72.81
$87.86
$91.80B0.27.93 million shs10.72 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$87.41
-6.7%
$96.62
$62.55
$177.37
$33.33B1.694.60 million shs7.22 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$4.03
+6.3%
$4.71
$3.53
$11.36
$478.72M1.477.68 million shs8.23 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$156.76
+0.2%
$158.20
$144.95
$175.97
$377.37B0.537.07 million shs6.53 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.56
0.0%
$28.19
$25.76
$44.20
$155.62B0.6245.47 million shs29.06 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.00%-4.27%-14.71%-1.68%-15.03%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-10.35%-17.50%+24.50%-48.36%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+2.54%-12.01%-35.73%-59.21%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+0.10%-3.47%+6.19%-3.32%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+2.34%-3.87%-4.90%-37.19%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.8313 of 5 stars
2.13.04.24.13.02.52.5
Moderna, Inc. stock logo
MRNA
Moderna
4.3196 of 5 stars
4.12.00.04.61.73.30.0
Novavax, Inc. stock logo
NVAX
Novavax
3.9653 of 5 stars
3.31.00.04.73.21.70.6
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.8929 of 5 stars
3.23.04.23.93.21.71.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9992 of 5 stars
4.23.04.24.82.63.33.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.29
Hold$86.3817.26% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.12
Hold$123.9641.81% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.67
Moderate Buy$25.00520.35% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.38
Hold$176.1412.36% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.33
Hold$36.9334.01% Upside

Current Analyst Ratings

Latest Vaccine Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/7/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$80.00 ➝ $78.00
2/7/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$78.00 ➝ $76.00
2/7/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$90.00 ➝ $84.00
2/6/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
1/31/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
1/24/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$170.00 ➝ $169.00
1/24/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00
1/23/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$82.00 ➝ $85.00
1/23/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
1/12/2024
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$125.00
1/9/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
(Data available from 2/12/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.12B3.39$6.42 per share11.47$18.26 per share4.03
Moderna, Inc. stock logo
MRNA
Moderna
$19.26B1.73$22.76 per share3.84$49.78 per share1.76
Novavax, Inc. stock logo
NVAX
Novavax
$1.98B0.24N/AN/A($8.08) per share-0.50
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.43$13.01 per share12.05$29.39 per share5.33
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.66$2.70 per share10.21$17.09 per share1.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$4.59B$4.5016.379.730.9620.89%38.85%13.60%4/25/2024 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
$8.36B-$9.35N/AN/AN/A-38.00%-2.14%-1.60%2/22/2024 (Confirmed)
Novavax, Inc. stock logo
NVAX
Novavax
-$657.94M-$6.37N/AN/AN/A-52.29%N/A-30.74%2/27/2024 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$13.8111.3514.292.6337.79%36.75%14.50%4/16/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3676.569.951.223.62%10.61%5.01%5/7/2024 (Estimated)

Latest Vaccine Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/22/2024N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$0.82N/A+$0.82N/AN/AN/A  
2/6/2024Q4 23
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.76$1.72-$0.04$2.30$7.10 billion$7.12 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    
1/23/202412/31/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.28$2.29+$0.01$2.91$21.02 billion$21.40 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.084.18%+3.32%68.44%8 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.04%+5.70%34.47%62 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.10%+12.89%466.67%14 Years

Latest Vaccine Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/1/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Quarterly$0.774.14%3/14/20243/15/20243/28/2024
1/2/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.193.03%2/16/20242/20/20243/5/2024
12/14/2023
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.43%1/25/20241/26/20243/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.08
1.46
1.20
Moderna, Inc. stock logo
MRNA
Moderna
0.04
2.46
2.35
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.69
0.64
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.37
1.21
0.96
Pfizer Inc. stock logo
PFE
Pfizer
0.63
2.38
2.05

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
82.33%
Moderna, Inc. stock logo
MRNA
Moderna
64.51%
Novavax, Inc. stock logo
NVAX
Novavax
71.46%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
68.40%
Pfizer Inc. stock logo
PFE
Pfizer
68.05%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
15.70%
Novavax, Inc. stock logo
NVAX
Novavax
0.90%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.20%
Pfizer Inc. stock logo
PFE
Pfizer
0.05%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.25 billion1.24 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900381.28 million321.42 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,992118.79 million117.72 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
155,8002.41 billion2.40 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.65 billion5.64 billionOptionable

Vaccine Stocks Headlines

SourceHeadline
Deutsche Bank AG Cuts Stock Position in Pfizer Inc. (NYSE:PFE)Deutsche Bank AG Cuts Stock Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - February 11 at 11:41 AM
Motley Fool: Investors may consider Pfizer as good medicineMotley Fool: Investors may consider Pfizer as good medicine
spokesman.com - February 11 at 8:33 AM
Letko Brosseau & Associates Inc. Has $69.96 Million Holdings in Pfizer Inc. (NYSE:PFE)Letko Brosseau & Associates Inc. Has $69.96 Million Holdings in Pfizer Inc. (NYSE:PFE)
marketbeat.com - February 10 at 11:50 AM
Latest News for Pfizer Stock (NYSE:PFE)Latest News for Pfizer Stock (NYSE:PFE)
benzinga.com - February 9 at 11:39 PM
Pfizer Inc. (NYSE:PFE) Shares Bought by Skandinaviska Enskilda Banken AB publPfizer Inc. (NYSE:PFE) Shares Bought by Skandinaviska Enskilda Banken AB publ
marketbeat.com - February 9 at 6:50 PM
Pfizer Is A Great Investment Over The Next Decade; BuyPfizer Is A Great Investment Over The Next Decade; Buy
seekingalpha.com - February 9 at 8:36 AM
S&P 500 rockets to new highs as earnings beat estimates (PFE)S&P 500 rockets to new highs as earnings beat estimates (PFE)
marketbeat.com - February 9 at 7:25 AM
State of New Jersey Common Pension Fund D Decreases Stock Position in Pfizer Inc. (NYSE:PFE)State of New Jersey Common Pension Fund D Decreases Stock Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - February 7 at 9:58 PM
Pfizer: The 6.3% Yield Is A AppealingPfizer: The 6.3% Yield Is A Appealing
seekingalpha.com - February 7 at 2:46 PM
Pfizers Problems Go Far Beyond Just Declining COVID RevenuePfizer's Problems Go Far Beyond Just Declining COVID Revenue
msn.com - February 7 at 2:46 PM
Paxlovid can lessen the chance of a severe COVID-19 illness. Why is it underused?Paxlovid can lessen the chance of a severe COVID-19 illness. Why is it underused?
finance.yahoo.com - February 7 at 9:46 AM
Arvinas and Pfizers Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast CancerArvinas and Pfizer's Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
tmcnet.com - February 6 at 6:07 PM
Pfizer Inc. (NYSE:PFE) Holdings Decreased by Vanguard Personalized Indexing Management LLCPfizer Inc. (NYSE:PFE) Holdings Decreased by Vanguard Personalized Indexing Management LLC
marketbeat.com - February 6 at 12:49 PM
Arvinas stock rises on fast track status for breast cancer candidate with PfizerArvinas stock rises on fast track status for breast cancer candidate with Pfizer
msn.com - February 6 at 7:27 AM
3 Magnificent Ultra-High-Yield Dividend Stocks That Are Screaming Buys in February3 Magnificent Ultra-High-Yield Dividend Stocks That Are Screaming Buys in February
fool.com - February 6 at 7:27 AM
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast CancerArvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
finance.yahoo.com - February 6 at 7:27 AM
Pharmaceutical Stocks - Best Pharmaceutical Stocks to Buy (PFE)Pharmaceutical Stocks - Best Pharmaceutical Stocks to Buy (PFE)
marketbeat.com - February 5 at 4:59 PM
Charles Schwab Investment Management Inc. Buys 9,393,992 Shares of Pfizer Inc. (NYSE:PFE)Charles Schwab Investment Management Inc. Buys 9,393,992 Shares of Pfizer Inc. (NYSE:PFE)
marketbeat.com - February 5 at 3:58 PM
PFE Feb 2024 19.000 callPFE Feb 2024 19.000 call
ca.finance.yahoo.com - February 5 at 2:44 PM
Spotlight on Pfizer: Analyzing the Surge in Options ActivitySpotlight on Pfizer: Analyzing the Surge in Options Activity
benzinga.com - February 5 at 2:44 PM
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care DisparitiesBreaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
finance.yahoo.com - February 5 at 2:44 PM
Markets suddenly price Eli Lilly stock for a breakout on earnings (PFE)Markets suddenly price Eli Lilly stock for a breakout on earnings (PFE)
marketbeat.com - February 5 at 11:16 AM
Pfizer: Simply Too Cheap To IgnorePfizer: Simply Too Cheap To Ignore
seekingalpha.com - February 4 at 12:38 PM
Massachusetts Financial Services Co. MA Has $2 Billion Stock Holdings in Pfizer Inc. (NYSE:PFE)Massachusetts Financial Services Co. MA Has $2 Billion Stock Holdings in Pfizer Inc. (NYSE:PFE)
marketbeat.com - February 4 at 8:55 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Novavax logo

Novavax

NASDAQ:NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

My Account -